Floatz logo

Carboplatin

Mismatch Repair Deficiency

Floor Backes, MDSmall moleculeEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Mismatch Repair Deficiency cohort.

Asset / SponsorPhaseRating
Nivolumab
7 Hills Pharma, LLC
Phase 2B
Pembrolizumab
Jennifer Leddon
Phase 2B
Cyclophosphamide
Jennifer Leddon
Phase 2B
Durvalumab
ImmunityBio, Inc.
Phase 2CCC
Atezolizumab
ImmunityBio, Inc.
Phase 2CCC

View all 25 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →